AU2016278088B2 - Use of cannabinoids in the treatment of epilepsy - Google Patents

Use of cannabinoids in the treatment of epilepsy Download PDF

Info

Publication number
AU2016278088B2
AU2016278088B2 AU2016278088A AU2016278088A AU2016278088B2 AU 2016278088 B2 AU2016278088 B2 AU 2016278088B2 AU 2016278088 A AU2016278088 A AU 2016278088A AU 2016278088 A AU2016278088 A AU 2016278088A AU 2016278088 B2 AU2016278088 B2 AU 2016278088B2
Authority
AU
Australia
Prior art keywords
cbd
seizures
solvent
syndrome
focal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016278088A
Other languages
English (en)
Other versions
AU2016278088A1 (en
Inventor
Emma CHEETHAM
Orrin Devinsky
Geoffrey Guy
Alice MEAD
Dominic Schiller
Stephen Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Research Uk Ltd
Original Assignee
Jazz Pharmaceuticals Res Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53784899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016278088(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Res Uk Ltd filed Critical Jazz Pharmaceuticals Res Uk Ltd
Publication of AU2016278088A1 publication Critical patent/AU2016278088A1/en
Application granted granted Critical
Publication of AU2016278088B2 publication Critical patent/AU2016278088B2/en
Priority to AU2021269374A priority Critical patent/AU2021269374B2/en
Assigned to JAZZ PHARMACEUTICALS RESEARCH UK LIMITED reassignment JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Request to Amend Deed and Register Assignors: GW Research Limited
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0203—Solvent extraction of solids with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2016278088A 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy Active AU2016278088B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021269374A AU2021269374B2 (en) 2015-06-17 2021-11-17 Use of cannabinoids in the treatment of epilepsy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1510664.4 2015-06-17
GB1510664.4A GB2539472A (en) 2015-06-17 2015-06-17 Use of cannabinoids in the treatment of epilepsy
PCT/GB2016/051792 WO2016203239A1 (en) 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021269374A Division AU2021269374B2 (en) 2015-06-17 2021-11-17 Use of cannabinoids in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
AU2016278088A1 AU2016278088A1 (en) 2018-01-18
AU2016278088B2 true AU2016278088B2 (en) 2021-08-19

Family

ID=53784899

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016278088A Active AU2016278088B2 (en) 2015-06-17 2016-06-16 Use of cannabinoids in the treatment of epilepsy
AU2021269374A Active AU2021269374B2 (en) 2015-06-17 2021-11-17 Use of cannabinoids in the treatment of epilepsy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021269374A Active AU2021269374B2 (en) 2015-06-17 2021-11-17 Use of cannabinoids in the treatment of epilepsy

Country Status (8)

Country Link
US (4) US10709671B2 (enExample)
EP (2) EP3310390A1 (enExample)
JP (2) JP6983076B2 (enExample)
AU (2) AU2016278088B2 (enExample)
GB (1) GB2539472A (enExample)
HK (1) HK1253580A1 (enExample)
MX (3) MX381089B (enExample)
WO (1) WO2016203239A1 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
AU2016222804C1 (en) 2015-02-25 2021-10-14 The Regents Of The University Of California 5HT agonists for treating disorders
US11216020B2 (en) 2015-05-04 2022-01-04 Johnson Controls Tyco IP Holdings LLP Mountable touch thermostat using transparent screen technology
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
DK3364993T3 (da) 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) * 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
SG11201909963YA (en) * 2017-04-26 2019-11-28 Cavion Inc Methods for treating dravet syndrome
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
IL301910A (en) * 2017-09-19 2023-06-01 Zynerba Pharmaceuticals Inc Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
GB2568471B (en) * 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) * 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572737A (en) * 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2020072773A1 (en) 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2586026A (en) * 2019-07-29 2021-02-03 Gw Res Ltd Use of cannabidol in the treatment of Dravet syndrome
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
JP7670700B2 (ja) 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
GB2588461A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
GB2588460A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) * 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2597323A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597283A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597300A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597288A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597305A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597286A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes
GB2597317A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597291A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597308A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597293A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597298A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with brain damage
GB2597287A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597297A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597299A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597302A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
GB2597303A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597301A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2601755A (en) * 2020-12-08 2022-06-15 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
US12036228B2 (en) 2022-04-12 2024-07-16 Shackelford Pharma Inc. Treatment of seizure disorders
US11944635B1 (en) 2023-07-24 2024-04-02 Poviva Corp Compositions and methods for treating epilepsy
US12023346B1 (en) 2023-07-24 2024-07-02 Poviva Corp Compositions and methods for treating epilepsy
US11931369B1 (en) 2023-07-24 2024-03-19 Poviva Corp Compositions and methods for treating epilepsy
US11986485B1 (en) 2023-07-24 2024-05-21 Poviva Corp Compositions and methods for treating epilepsy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093255A1 (en) * 2011-01-04 2012-07-12 Gw Pharma Limited Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
WO2015193668A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy
WO2016059404A1 (en) * 2014-10-14 2016-04-21 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304669A (en) 1940-08-16 1942-12-08 Adams Roger Isolation of cannabidiol
JPS5430146A (en) 1977-08-05 1979-03-06 Microbial Chem Res Found Novel anthracycline derivatives and their preparation
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2380129B (en) 2001-02-14 2004-08-11 Gw Pharma Ltd Pharmaceutical formulations
EP2298284A3 (en) 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
GB2381194A (en) 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
JP4657716B2 (ja) 2002-08-14 2011-03-23 ジーダブリュー・ファーマ・リミテッド 植物材料からの薬学的に活性な成分の抽出の改良
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
KR101008609B1 (ko) 2002-08-14 2011-01-17 지더블유 파마 리미티드 점막투여용 칸나비노이드 액체 제형
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
US20040110828A1 (en) 2002-11-27 2004-06-10 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
WO2005065069A2 (en) 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
WO2006017892A1 (en) 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
EP1811983B1 (en) 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
AU2006297300B2 (en) 2005-09-29 2012-05-10 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
ES2581212T3 (es) * 2005-11-07 2016-09-02 Murty Pharmaceuticals, Inc. Administración mejorada de tetahidrocannabinol
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US20070173770A1 (en) 2006-01-23 2007-07-26 The Medical House Plc Injection device
US9877928B2 (en) 2006-05-30 2018-01-30 Air Systems, Inc. Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US20110150825A1 (en) 2006-11-14 2011-06-23 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
WO2008094181A2 (en) 2007-02-01 2008-08-07 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
CN101040855A (zh) 2007-04-12 2007-09-26 杨喜鸿 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
EP2023121A1 (en) 2007-07-06 2009-02-11 Bp Oil International Limited Optical cell
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
ES2534900T3 (es) 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
JP2010535774A (ja) 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
US9023322B2 (en) 2008-03-26 2015-05-05 Stichting Sanammad Chewing gum compositions comprising cannabinoids
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2475183B (en) 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2341903A1 (en) 2008-07-31 2011-07-13 Bionorica Research GmbH Cannabinoids for use in treating or preventing cognitive impairment and dementia
HUE032158T2 (en) * 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
US20100273895A1 (en) 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
AU2009345154A1 (en) 2009-04-29 2011-12-22 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
EP2448567B1 (en) 2009-06-29 2013-03-13 Bender Analytical Holding B.V. Drug delivery system comprising polyoxazoline and a bioactive agent
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US20110033529A1 (en) 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487183B (en) 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US20130143894A1 (en) 2010-06-07 2013-06-06 vadel Pharma Inc. Oral spray formulations ad methods for administration of sildenafil
EP2600850B1 (en) 2010-08-04 2018-10-17 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
WO2012033478A1 (en) 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
CA2737447A1 (en) 2011-04-27 2012-10-27 Antony Paul Hornby Hayley's comet
US9104993B2 (en) 2011-04-28 2015-08-11 Lantronix, Inc. Asset management via virtual tunnels
GB2491118B (en) 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
GB2504263B (en) 2012-06-08 2015-09-16 Gw Pharma Ltd Synergistic therapies for neuroprotection
DE102012105063C5 (de) 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
EP2943463B1 (en) 2013-01-08 2021-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fluorinated cbd compounds, compositions and uses thereof
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
RS60295B1 (sr) 2013-03-19 2020-07-31 Univ Pompeu-Fabra Antagonisti kanabionoidnih receptora cb1 za upotrebu u lečenju oboljenja vezanih za abnormalnosti neuronskih dendrita
JP6300613B2 (ja) 2013-04-09 2018-03-28 キヤノン株式会社 トナー用樹脂およびトナー
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
DK3062606T3 (da) 2013-10-29 2019-06-24 Biotech Inst Llc Forædling, fremstilling, forarbejdning og anvendelse af speciel cannabis
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US9259449B2 (en) * 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
CN103913888B (zh) 2014-03-28 2016-08-17 京东方科技集团股份有限公司 一种彩膜基板、显示装置及彩膜基板的制造方法
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20170224634A1 (en) 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CN106999598B (zh) 2014-05-29 2022-02-08 鲜切发展有限责任公司 稳定的大麻素类化合物制剂
WO2015187988A1 (en) 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
GB2527591A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
CA2990071C (en) 2014-07-14 2023-01-24 Librede Inc. Production of cannabigerolic acid
US9492438B2 (en) 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
CA2859934A1 (en) 2014-09-22 2016-03-22 A. Paul Hornby Hayley's comet ii
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US9730911B2 (en) 2014-10-21 2017-08-15 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
CN104490873A (zh) 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
AU2015351937A1 (en) 2014-11-26 2017-06-29 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
US20160256410A1 (en) 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
CA2982250A1 (en) 2015-03-19 2016-09-22 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
EP3288592A4 (en) 2015-04-28 2019-01-09 The Regents of The University of California USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS
CN107849021A (zh) 2015-05-11 2018-03-27 阿比德治疗公司 治疗炎症或神经性疼痛的方法
CA2986268C (en) 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
WO2017203529A1 (en) 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
EP3307266A4 (en) 2015-06-11 2019-01-16 One World Cannabis Ltd Novel CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM)
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20170008869A1 (en) 2015-07-10 2017-01-12 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
GB2542797A (en) 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
NZ745595A (en) 2016-01-29 2019-12-20 Univ Mississippi Biologically active cannabidiol analogs
WO2017139496A1 (en) 2016-02-09 2017-08-17 Cevolva Biotech, Inc. Microbial engineering for the production of cannabinoids and cannabinoid precursors
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
CA3025702C (en) 2016-05-27 2022-12-20 Insys Development Company, Inc. Stable cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
JP2020514282A (ja) 2016-12-20 2020-05-21 ティルレイ，インコーポレイティド 新規カンナビノイド組成物および使用方法
CN108236608B (zh) 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
JP2020517727A (ja) 2017-04-27 2020-06-18 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
IT201700085508A1 (it) 2017-07-26 2019-01-26 Inalco S R L Metodo per la produzione di cannabinoidi da varietà di canapa industriale
US10925525B2 (en) 2017-08-18 2021-02-23 Canon U.S.A., Inc. Combined pulse oximetry and diffusing wave spectroscopy system and control method therefor
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11498018B2 (en) 2017-11-27 2022-11-15 Vasilios (Bill) Panagiotakopoulos Extraction and purification of cannabinoid compounds
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2019129358A1 (en) 2017-12-29 2019-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Methods providing transmission and/or searching of encrypted data and related devices
GB2572125B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572737A (en) 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CA3098010A1 (en) 2018-04-27 2019-10-31 Thomas Jefferson University Nanospun hemp-based materials
WO2019211795A1 (en) 2018-05-03 2019-11-07 Radient Technologies Inc. Continuous flow microwave-assisted extraction of a cannabis biomass
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
GB2579179A (en) 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2580881A (en) 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2580653A (en) 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB2581517A (en) 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2581987B (en) 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
GB2584140A (en) 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
CN110215443A (zh) 2019-07-08 2019-09-10 云南绿新生物药业有限公司 一种抗衰老、改善睡眠软胶囊的制备方法
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2586026A (en) 2019-07-29 2021-02-03 Gw Res Ltd Use of cannabidol in the treatment of Dravet syndrome
CN110279617A (zh) 2019-08-05 2019-09-27 云南绿新生物药业有限公司 一种含火麻精油的洗发水及其制备方法
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB2588461A (en) 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
GB2589306A (en) 2019-10-25 2021-06-02 Gw Res Ltd Use of cannabidiol preparations in the treatment of fragile X syndrome
GB2588457B (en) 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201918846D0 (en) 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11409517B2 (en) 2020-06-08 2022-08-09 Microsoft Technology Licensing, Llc Intelligent prefetching for OS components
GB2597323A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597309A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597308A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597315A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597316A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597317A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597318A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597281A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB2597312A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202014250D0 (en) 2020-09-10 2020-10-28 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20220087951A1 (en) 2020-09-18 2022-03-24 GW Research Limited Use of cannabinoids in the treatment of epilepsy
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2601755A (en) 2020-12-08 2022-06-15 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
TW202237554A (zh) 2020-12-15 2022-10-01 英商吉偉研究有限公司 新穎化合物、其製備方法及其用途
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
US11815187B2 (en) 2022-01-26 2023-11-14 Maag Germany Gmbh 3-port valve

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093255A1 (en) * 2011-01-04 2012-07-12 Gw Pharma Limited Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
WO2015193668A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy
WO2016059404A1 (en) * 2014-10-14 2016-04-21 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GW Pharmaceuticals Announces Epidiolex Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome", (2014-06-06) *
GW Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for Epidiolex", URL: http://www.gwpharm.com/GW%20Pharmaceuticals %20Provides%20Update%200n%200rphan%2OProgram%20in%20Childhood %20Epilepsy%20for%2OEpidiolex.aspx *

Also Published As

Publication number Publication date
US20200297656A1 (en) 2020-09-24
GB201510664D0 (en) 2015-07-29
MX2017016212A (es) 2018-04-13
AU2021269374A1 (en) 2021-12-16
US20220387348A1 (en) 2022-12-08
NZ738403A (en) 2024-07-26
JP6983076B2 (ja) 2021-12-17
CA2989779A1 (en) 2016-12-22
MX2021003331A (es) 2022-11-28
MX381089B (es) 2025-03-12
US10709671B2 (en) 2020-07-14
AU2021269374B2 (en) 2023-12-14
EP3310390A1 (en) 2018-04-25
US20240350428A1 (en) 2024-10-24
US12064399B2 (en) 2024-08-20
JP2018521042A (ja) 2018-08-02
HK1253580A1 (zh) 2019-06-21
US20170007551A1 (en) 2017-01-12
AU2016278088A1 (en) 2018-01-18
WO2016203239A1 (en) 2016-12-22
JP2022033807A (ja) 2022-03-02
EP3984531A1 (en) 2022-04-20
US11357741B2 (en) 2022-06-14
GB2539472A (en) 2016-12-21
MX2022015027A (es) 2023-01-04

Similar Documents

Publication Publication Date Title
AU2021269374B2 (en) Use of cannabinoids in the treatment of epilepsy
AU2022209295B2 (en) Use of cannabidiols in the treatment of epilepsy
AU2021204353B2 (en) Use of cannabinoids in the treatment of epilepsy
AU2015332208B2 (en) Use of cannabidiol in the treatment of Tuberous Sclerosis Complex
WO2016059404A1 (en) Use of cannabidiol in the treatment of epilepsy
CA2989779C (en) Use of cannabinoids in the treatment of epilepsy
HK40073373A (en) Use of cannabidiol for the treatment of focal seizures in dravet syndrome
HK40039512A (en) Use of cannabinoids in the treatment of epilepsy
HK1241723B (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
HK1241723A1 (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
HK1241740B (en) Use of cannabinoids in the treatment of atonic seizures in lennox-gastaut syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED

Free format text: FORMER NAME(S): GW RESEARCH LIMITED